Assenagon Asset Management S.A. Akebia Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$0.86 - $1.63 $497,798 - $943,502	-578,836 Reduced 73.23%	211,647 $215,000
Q1 2024 Apr 24, 2024	BUY	$1.27 - $2.24 $1 Million - $1.77 Million	790,483 New	790,483 $1.45 Million
Q1 2023 Apr 18, 2023	BUY	$0.56 - $1.15 $6,972 - $14,317	12,450 New	12,450 $6,000
Q2 2022 Jul 27, 2022	SELL	$0.32 - $0.67 $33,309 - $69,741	-104,092 Closed	0 $0
Q1 2022 Apr 25, 2022	BUY	$0.72 - $2.93 $74,946 - $304,989	104,092 New	104,092 $75,000
Q1 2020 Apr 17, 2020	SELL	$4.1 - $10.24 $49,798 - $124,375	-12,146 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$3.16 - $6.73 $38,381 - $81,742	12,146 New	12,146 $77,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.